GlassScriptPhysician profile
Huiyuan Jiang
NPI 1891718243
$4,381.31
in general payments reported to CMS, 2019-2025
30 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,157 · 2020: $331 · 2021: $235 · 2022: $101 · 2023: $519 · 2024: $653 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,556.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,796.06 | 2019-2021 | |
| Ucb, INC. | $592.49 | 2020-2025 | Fintepla, Nayzilam, Briviact |
| Neurelis, INC. | $465.51 | 2022-2024 | Valtoco |
| Aquestive Therapeutics, INC. | $277.39 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $181.75 | 2024-2025 | Daybue |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $157.45 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $127.91 | 2019-2020 | |
| Biomarin Pharmaceutical INC. | $93.40 | 2024 | Palynziq |
| Eisai INC. | $85.59 | 2019 | |
| Jazz Pharmaceuticals INC. | $63.29 | 2019-2025 | |
| Novo Nordisk INC | $48.54 | 2024 | Sogroya |
| Sarepta Therapeutics, INC. | $45.01 | 2019-2024 | Elevidys |
| Supernus Pharmaceuticals, INC. | $44.40 | 2019 | |
| Greenwich Biosciences, INC. | $42.73 | 2020-2021 | |
| Ptc Therapeutics, INC. | $39.62 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $30.78 | 2024-2025 | Skytrofa |
| Tolmar Pharmaceuticals, INC. | $28.98 | 2022 | |
| Alexion Pharmaceuticals, INC. | $28.10 | 2019-2025 | Koselugo |
| Kyowa Kirin, INC. | $25.88 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $25.48 | 2024 | |
| Electromed, INC. | $24.94 | 2019 | |
| Neurocrine Biosciences, INC. | $22.32 | 2025 | |
| Tolmar, INC. | $20.84 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.80 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $18.51 | 2019 | |
| Xeris Pharmaceuticals, INC. | $17.58 | 2025 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $16.52 | 2023 | Aptiom |
| Cranial Technologies, INC | $14.29 | 2024 | Doc Band |
| Merz North America, INC. | $13.55 | 2019 | |
| Zogenix INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huiyuan Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.